MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27

C Wan1, S Hou2, R Ni2

  • 1School of Public Health, Nantong University, Nantong, People's Republic of China.

Oncogene
|December 17, 2013
PubMed

Insights

MIF4G domain containing protein (MIF4GD) stabilizes the cell cycle regulator p27, inhibiting hepatocellular carcinoma (HCC) cell proliferation and tumor growth. Low MIF4GD and p27 levels predict poor HCC prognosis.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Cycle Regulation

Background:

  • The cyclin-dependent kinase (CDK) inhibitor p27(kip1) is vital for cell cycle control and cancer development.
  • Identifying novel regulators of p27 is crucial for understanding and treating hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To identify novel binding partners of p27.
  • To investigate the functional role of MIF4G domain containing protein (MIF4GD) in p27 regulation and HCC progression.

Main Methods:

  • Yeast two-hybrid screening to identify p27 interacting proteins.
  • Immunoprecipitation and GST pull-down assays to confirm protein interactions.
  • Cellular assays (proliferation, cell cycle analysis), in vivo xenograft models, and analysis of clinical HCC tissues.

Main Results:

  • MIF4GD was identified as a novel binding partner of p27.
  • MIF4GD binding stabilizes p27 by inhibiting CDK2-mediated phosphorylation, reducing HCC cell proliferation and tumor growth.
  • Low expression of MIF4GD and p27 correlates with poor prognosis in HCC patients.

Conclusions:

  • MIF4GD acts as a novel regulator of p27 stability and function in HCC.
  • The MIF4GD-p27 interaction represents a potential therapeutic target for HCC treatment.
  • MIF4GD and p27 expression levels can serve as prognostic biomarkers for HCC.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

2.5K